Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

StatusRecruiting

PhasePhase 2

SponsorEmory University

Started2024-12-13

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Enrollment reduced 50% 20 → 10 participants

See other at-risk trials from Emory University

Amendment history

2026-09-17

Enrollment reduced: 20 → 10 participants

2025-11-07

Study Identification, Study Status, Oversight, Contacts/Locations v5

Study sitescontacts updated at 1 of 1 site

2025-01-17

Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v4

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2024-11-01→confirmed 2024-12-13

Study sitesdetails revised at 1 of 1 site

2024-09-05

Study Status v3

Start date2024-08-01→2024-11-01

2024-06-05

Study Status v2

Start date2024-03-31→2024-08-01

2024-01-05

Study Status v1

Start date2023-10-31→2024-03-31

2023-08-22

Original filing

Emory University

371 trials monitored

See 23 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes involving the middle of the chest. Proton therapy is a type of radiation treatment that kills cancer cells while avoiding surrounding healthy tissue. Proton beam therapy is sometimes used after cancer surgery to reduce the risk of cancer recurrence (coming back). Giving proton beam radiation therapy may work better than conventional radiation treatment after surgery in patients with non-small cell lung cancer.

Trial Details

NCT Number	NCT06008730
Lead Sponsor	Emory University Collaborators: National Cancer Institute (NCI)
Conditions	Resectable Lung Non-Small Cell Carcinoma
Enrollment	10 participants
Start Date	2024-12-13
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-16